- Ritter is a director at Slingshot Biosciences, Quantum Circuits, Elephas Biosciences and Enumerix
- Prior to ARCH, Ritter was an associate with the University of Chicago Innovation Fund
- In September, ARCH announced the closing of ARCH Venture Fund XIII at more than $3 billion
ARCH Venture Partners, an early-stage life sciences and technology venture firm, has promoted Corey Ritter to partner.
“Corey’s contributions have been crucial to the growth and success of numerous ARCH portfolio companies,” ARCH co-founder and managing director Keith Crandell said in a statement. “We look forward to seeing his continued impact in this new role as we work together to build the next generation of industry-leading companies.”
Ritter joined ARCH Venture Partners in 2018. He is a director at Slingshot Biosciences, Quantum Circuits, Elephas Biosciences and Enumerix. He also co-founded ARCH portfolio companies Scale Biosciences and Vizgen.
Prior to ARCH, Ritter was an associate with the University of Chicago Innovation Fund
In September, ARCH announced the closing of ARCH Venture Fund XIII at more than $3 billion.
- Ritter is a director at Slingshot Biosciences, Quantum Circuits, Elephas Biosciences and Enumerix
- Prior to ARCH, Ritter was an associate with the University of Chicago Innovation Fund
- In September, ARCH announced the closing of ARCH Venture Fund XIII at more than $3 billion
ARCH Venture Partners, an early-stage life sciences and technology venture firm, has promoted Corey Ritter to partner.
“Corey’s contributions have been crucial to the growth and success of numerous ARCH portfolio companies,” ARCH co-founder and managing director Keith Crandell said in a statement. “We look forward to seeing his continued impact in this new role as we work together to build the next generation of industry-leading companies.”
Ritter joined ARCH Venture Partners in 2018. He is a director at Slingshot Biosciences, Quantum Circuits, Elephas Biosciences and Enumerix. He also co-founded ARCH portfolio companies Scale Biosciences and Vizgen.
Prior to ARCH, Ritter was an associate with the University of Chicago Innovation Fund
In September, ARCH announced the closing of ARCH Venture Fund XIII at more than $3 billion.
